← Tutti gli studi Monitoraggio

In-Hospital Diabetes Management by a Diabetes Team and Insulin Titration Algorithms Based on Continuous Glucose Monitoring or Point-of-Care Glucose Testing in Patients With Type 2 Diabetes (DIATEC): A Randomized Controlled Trial.

Olsen MT, et al. · 2025
PubMed 39887698 ↗DOI: 10.2337/dc24-2222Diabetes care
🌱 La lettura di LEO
📉 Lavora su: Stabilità nel tempo · lente Traiettoria · il corpo nel tempo
tocca anche 💊 Terapia🛡️ Protezione d'organo
RCT (prova forte) — bicentrico, contesto ospedaliero
La domanda

Nei pazienti ospedalizzati non in terapia intensiva con diabete tipo 2, la titolazione dell'insulina guidata da CGM migliora il tempo in range rispetto al glucometro capillare (POC)?

Cosa hanno trovato

RCT a due centri (DIATEC), 166 pazienti non-UTI con T2D; team diabetologici titolavano insulina con algoritmi basati su CGM o su test capillare (POC). TIR (3,9-10,0 mmol/L) mediano 77,6% (IQR 24,4) con CGM vs 62,7% (IQR 31,5) con POC (P<0,001), +15 punti percentuali. TAR >10,0 mmol/L 21,1% (IQR 24,8) vs 36,5% (IQR 30,3) (P=0,001). TBR <3,9 mmol/L ridotto: differenza relativa vs POC 0,57 (IC95% 0,34-0,97; P=0,042). Eventi ipoglicemici prolungati IRR 0,13 (IC95% 0,04-0,46; P=0,001). CV medio 25,4% (DS 6,3) vs 28,0% (DS 8,2) (P=0,024). Insulina totale 24,1 (DS 13,9) vs 29,3 (DS 13,9) UI/die (P=0,049). Composito di complicanze IRR 0,76 (IC95% 0,59-0,98; P=0,032).

Cosa significa per te

In ospedale, per pazienti con tipo 2, guidare la terapia insulinica con il monitoraggio continuo (CGM) invece del pungidito aumenta il tempo in range e riduce iperglicemia, ipoglicemie prolungate, variabilità, consumo di insulina e complicanze in degenza. Risultato riferito al contesto ospedaliero gestito da team esperti; non è un'indicazione di dosaggio (la titolazione resta decisione clinica). Non riguarda direttamente il tipo 1.

Abstract (in lingua originale)

OBJECTIVE: The Diabetes Team and CGM in Managing Hospitalized Patients With Diabetes (DIATEC) trial investigates the glycemic and clinical effects of inpatient continuous glucose monitoring (CGM)-guided insulin titration by diabetes teams. RESEARCH DESIGN AND METHODS: This two-center trial randomized 166 non-intensive care unit patients with type 2 diabetes. Diabetes management was performed by regular staff, guided by diabetes teams using insulin titration algorithms based on either point-of-care glucose testing or CGM. The primary outcome was the difference in time in range (TIR) (3.9-10.0 mmol/L) between the two arms. Outcomes were assessed during hospitalization. RESULTS: The CGM arm achieved a higher median (interquartile range [IQR]) TIR of 77.6% (24.4%) vs. 62.7% (31.5%) in the POC arm (P < 0.001). Median (IQR) time above range (TAR) >10.0 mmol/L was lower in the CGM arm at 21.1% (24.8%) vs. 36.5% (30.3%) in the POC arm (P = 0.001), and time below range (TBR) <3.9 mmol/L was reduced by CGM, with a relative difference to POC of 0.57 (95% CI 0.34-0.97; P = 0.042). Prolonged hypoglycemic events decreased (incidence rate ratio [IRR] 0.13; 95% CI 0.04-0.46; P = 0.001), and the mean (SD) coefficient of variation was lower in the CGM arm at 25.4% (6.3%) vs. 28.0% (8.2%) in the POC arm (P = 0.024). Mean (SD) total insulin doses were reduced in the CGM arm at 24.1 (13.9) vs. 29.3 (13.9) IU/day in the POC arm (P = 0.049). A composite of complications was lower in the CGM arm (IRR 0.76; 95% CI 0.59-0.98; P = 0.032). CONCLUSIONS: In-hospital CGM increased TIR by 15 percentage points, mainly by reducing TAR. CGM also lowered TBR, glycemic variability, prolonged hypoglycemic events, insulin usage, and in-hospital complications.
💬 Chiedi a LEO di spiegartelo
Come leggerlo: è uno studio scientifico peer-reviewed. Le evidenze aiutano a capire i trend, ma un singolo studio non è una prescrizione: parlane col tuo diabetologo prima di cambiare dieta o terapia.